Skip to main content
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track RIGL — free
$42.53 -0.39 (-0.91%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$800.84M
Shares
18.83M
Volume · Nov 18 304.84K Avg daily vol (3M) 252.93K

Rigel Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Rigel Pharmaceuticals Inc (RIGL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Rigel Pharmaceuticals Inc (RIGL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-05
Rigel Pharmaceuticals Inc (RIGL) Q3 2026 Earnings Call Transcript
Confident tone R289 development in lower-risk MDS Vepenu commercial launch Commercial portfolio performance
Revenue
$80.89M
▲ 16.5% YoY
Diluted EPS
$0.65
▼ 55.5% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-11-05
Rigel Pharmaceuticals Inc (RIGL) November 5, 2026 Investor Update
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Rigel Pharmaceuticals Inc (RIGL) September 15, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Rigel Pharmaceuticals Inc (RIGL) September 10, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Capital Markets Day
Investor event
2026-08-13
Rigel Pharmaceuticals Inc (RIGL) August 13, 2026 Capital Markets Day
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2026 Earnings Call Transcript
Confident tone Pipeline / R289 Development Breast Cancer Market Opportunity Commercial Launch Execution
Revenue
$78.70M
▼ 22.6% YoY
Diluted EPS
$0.88
▼ 73.2% YoY
Gross margin
89.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Rigel Pharmaceuticals Inc (RIGL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Rigel Pharmaceuticals Inc (RIGL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2026 Earnings Call Transcript
Confident tone R289 pipeline in lower-risk MDS Net product sales growth 2026 financial guidance and profitability
Revenue
$58.82M
▲ 10.3% YoY
Diluted EPS
$0.44
▼ 30.2% YoY
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Transcript
Confident tone R289 pipeline in lower-risk MDS Net product sales growth Competitive landscape and unmet need
Revenue
$69.80M*
▲ 21.2% YoY
Gross margin
91.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Call Transcript
Confident tone R289 development in lower-risk MDS Olutasidenib pipeline expansion Commercial product sales growth
Revenue
$69.46M
▲ 25.6% YoY
Diluted EPS
$1.46
▲ 108.6% YoY
Gross margin
93.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Transcript
Revenue
$101.69M
▲ 176% YoY
Diluted EPS
$3.28
Gross margin
95.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Transcript
Confident tone R289 pipeline in MDS Commercial portfolio of three products Olutasidenib expansion into glioma
Revenue
$53.33M
▲ 80.6% YoY
Diluted EPS
$0.63
Gross margin
91.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Transcript
Confident tone Commercial portfolio growth and product sales Pipeline development - R289 in lower-risk MDS Olutasidenib collaborations and IDH1 mutant cancers
Revenue
$57.60M*
▲ 60.9% YoY
Gross margin
89.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Transcript
Confident tone Commercial growth and product sales GAVRETO integration and transition Pipeline development and R289
Revenue
$55.31M
▲ 96.6% YoY
Diluted EPS
$0.70
Gross margin
85.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rigel Pharmaceuticals Inc (RIGL) Q2 2024 Earnings Call Transcript
Confident tone GAVRETO acquisition and launch R289 pipeline in MDS TAVALISSE commercial performance
Revenue
$36.84M
▲ 37% YoY
Diluted EPS
$-0.06
Gross margin
92.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript
Confident tone TAVALISSE demand growth REZLIDHIA uptake GAVRETO acquisition
Revenue
$29.53M
▲ 13.3% YoY
Diluted EPS
$-0.47
Gross margin
93.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Rigel Pharmaceuticals Inc (RIGL) Q4 2023 Earnings Call Transcript
Confident tone GAVRETO acquisition and commercial opportunity TAVALISSE and REZLIDHIA commercial performance Market expansion via RET testing and biomarker awareness
Revenue
$35.79M*
▼ 30.2% YoY
Gross margin
89.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2023 Earnings Call Transcript
Revenue
$28.13M
▲ 25.5% YoY
Diluted EPS
$-0.33
Gross margin
95.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rigel Pharmaceuticals Inc (RIGL) Q2 2023 Earnings Call Transcript
Revenue
$26.89M
▼ 9.8% YoY
Diluted EPS
$-0.38
Gross margin
96.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rigel Pharmaceuticals Inc (RIGL) Q1 2023 Earnings Call Transcript
Revenue
$26.07M
▲ 55.8% YoY
Diluted EPS
$-0.80
Gross margin
96.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Rigel Pharmaceuticals Inc (RIGL) Q4 2022 Earnings Call Transcript
Revenue
$51.28M*
▲ 151.3% YoY
Gross margin
99.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Rigel Pharmaceuticals Inc (RIGL) Q3 2022 Earnings Call Transcript
Revenue
$22.41M
▲ 4% YoY
Diluted EPS
$-1.10
Gross margin
98.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rigel Pharmaceuticals Inc (RIGL) Q2 2022 Earnings Call Transcript
Revenue
$29.82M
▲ 13.5% YoY
Diluted EPS
$-0.80
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rigel Pharmaceuticals Inc (RIGL) Q1 2022 Earnings Call Transcript
Revenue
$16.73M
▼ 79.3% YoY
Diluted EPS
$-1.60
▼ 172.7% YoY
Gross margin
99.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Rigel Pharmaceuticals Inc (RIGL) Q4 2021 Earnings Call Transcript
Revenue
$20.41M*
▲ 10.6% YoY
Gross margin
97.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rigel Pharmaceuticals Inc (RIGL) Q3 2021 Earnings Call Transcript
Revenue
$21.54M
▲ 17.2% YoY
Diluted EPS
$-1.20
Gross margin
99.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rigel Pharmaceuticals Inc (RIGL) Q2 2021 Earnings Call Transcript
Revenue
$26.27M
▲ 63.9% YoY
Diluted EPS
$-0.80
Gross margin
99.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2021 Earnings Call Transcript
Revenue
$81.02M
▲ 45.3% YoY
Diluted EPS
$2.20
▲ 69.2% YoY
Gross margin
99.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Rigel Pharmaceuticals Inc (RIGL) Q4 2020 Earnings Call Transcript
Revenue
$18.45M
▲ 19.8% YoY
Gross margin
94.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Rigel Pharmaceuticals Inc (RIGL) Q3 2020 Earnings Call Transcript
Revenue
$18.39M
▼ 11.8% YoY
Diluted EPS
$-0.80
Gross margin
87.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
Revenue
$16.02M
▲ 53.9% YoY
Diluted EPS
$-1.00
Gross margin
91.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2020 Earnings Call Transcript
Revenue
$55.76M
▲ 341.7% YoY
Diluted EPS
$1.30
Gross margin
22.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Rigel Pharmaceuticals Inc (RIGL) Q4 2019 Earnings Call
Revenue
$15.40M
▼ 59.3% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–35 of 35 webcasts
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 182 filings 156 filers Visit website Investor relations